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Abstract
Background: Age-related macular degeneration (AMD) is the leading cause of vision loss in Western societies with a
strong genetic component. Candidate gene studies as well as genome-wide association studies strongly implicated
genetic variations in complement genes to be involved in disease risk. So far, no association of AMD with complement
component 4 (C4) was reported probably due to the complex nature of the C4 locus on chromosome 6.
Methods: We used multiplex ligation-dependent probe amplification (MLPA) to determine the copy number of the C4
gene as well as of both relevant isoforms, C4A and C4B, and assessed their association with AMD using logistic
regression models.
Results: Here, we report on the analysis of 2645 individuals (1536 probands and 1109 unaffected controls), across three
different centers, for multiallelic copy number variation (CNV) at the C4 locus. We find strong statistical significance for
association of increased copy number of C4A (OR 0.81 (0.73; 0.89);P = 4.4 × 10−5), with the effect most pronounced in
individuals over 78 years (OR 0.67 (0.55; 0.81)) and females (OR 0.77 (0.68; 0.87)). Furthermore, this association is
independent of known AMD-associated risk variants in the nearby CFB/C2 locus, particularly in females and in
individuals over 78 years.
Conclusions: Our data strengthen the notion that complement dysregulation plays a crucial role in AMD etiology,
an important finding for early intervention strategies and future therapeutics. In addition, for the first time, we provide
evidence that multiallelic CNVs are associated with AMD pathology.
Keywords: Age-related macular degeneration, AMD, C4, Complement, Copy number variation (CNV), Multiallelic,
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Background
Age-related macular degeneration (AMD) is the leading
cause of severe vision loss in aging societies [1–3]. An
early sign of AMD is the appearance of the so-called
drusen, which are yellowish extracellular deposits of
protein and lipid material within and beneath the ret-
inal pigment epithelium (RPE). Late-stage AMD can
manifest essentially as two distinct forms—geographic
atrophy (GA) and neovascular (NV) AMD, with both
late-stage forms in a proportion of cases presenting in
the same or in different eyes of an individual. GA oc-
curs in up to 50 % of cases and is clinically defined as a
distinct area of RPE cell atrophy with slow progression
over the years. NV AMD describes the growth of blood
vessels beneath and within the retina and is mostly
characterized by hemorrhagic detachment of the RPE
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or the retina and eventually widespread RPE atrophy.
Progression to visual loss can be rapid in NV AMD [4].
Over the past several years, genome-wide associ-
ation studies and large scale re-sequencing projects
have identified a number of single nucleotide variants
(SNVs) enriched in complement and complement-re-
lated genes that confer a strong risk for AMD [3, 5–8]. Re-
cently, a genome-wide association study conducted by the
International AMD Genomics consortium (IAMDGC)
identified 52 independent genetic signals at 34 loci to be
associated with AMD risk [9], explaining around half of
the genomic heritability of the disease. Six out of those 34
loci harbor one or more complement or complement-
related genes.
Assessment of structural variation, particularly in
duplicated regions of the genome, and its contribu-
tion to disease still remains a challenge for most
case-control studies [10, 11]. Multiallelic loci are es-
pecially problematic, due to a lack of suitable tagging
variants and a dearth of probes on commercial micro-
arrays in duplication rich regions of the genome [12].
We and others have previously demonstrated that
multiallelic loci can be genotyped economically and accur-
ately using PCR-based quantitative techniques [13–15].
Here, we applied multiplex ligation-dependent probe
amplification (MLPA) [16] to examine the role of the mul-
tiallelic complement component 4 (C4) copy number vari-
ations (CNVs) as part of the classical complement
pathway in AMD etiology.
In this study, we successfully genotyped CNVs for
C4 and its relevant isoforms (C4A, C4B) in 2645
individuals from three large AMD cohorts from
Australia and Germany. We identify strong statistical
significance for a protective association of C4A copy
number and AMD. Stratification of individuals based
on age and gender revealed that the protective effect
increases with increasing age and is stronger in females. In
addition, this association appears to be independent of
other, strongly associated AMD variants at the nearby
CFB/C2 locus. These data implicate multiallelic CNV of
the C4 locus in AMD susceptibility, providing further evi-
dence for the crucial role of complement dysregulation in
AMD etiology.
Methods
Subjects
Three independent patient cohorts were included in our
study comprising a total of 1536 unrelated Caucasian pa-
tients with clinically documented late-stage AMD (cases)
and 1109 unrelated individuals with comparable age
range and ethnicity without signs of macular disease
(controls). The controls were often spouses of AMD pa-
tients (Table 1). Cases and controls were examined by
trained ophthalmologists. Fundus photographs were
graded according to standardized classification systems
as described previously [17, 18]. The study was con-
ducted at all sites in strict adherence to the tenets of the
Declaration of Helsinki and was approved by the re-
spective Ethics Committees of the Human Research
and Ethics Committee of the Royal Victorian Eye and
Ear Hospital (RVEEH), Melbourne, the University of
Tasmania, Australia and at the University Eye Clinics
of Würzburg, München and Tübingen, Germany.
Genotyping by MLPA
Genomic DNA was extracted from peripheral blood
leukocytes according to established protocols. MLPA
was performed according to previous reports [19, 20]
with custom-made oligonucleotide probes (Additional
file 1: Table S1). For each PCR reaction, 1 μl was mixed
with 8.8 μl of HIDI formamide and 0.2 μl of LIZ500
size standard (Applied Biosystems). PCR products were
separated by capillary electrophoresis on a sequence
platform (3130xl Genetic Analyzer, Applied Biosystems;
Foster City, CA, USA). The program Peak Scanner 2
(Applied Biosystems) was used to extract the dosages
(height) of each peak. Copy number analysis was per-
formed by dividing the peak height of each test probe
(C4A, C4B, or C4-ex30 representing the isoforms C4A
and C4B or the total C4 copy number, respectively), by
the sum peak heights from two control loci (EP300 and
CREBBP) to generate a normalized ratio. The normal-
ized ratio was then divided by the median of all ratios
for the corresponding peak, yielding a normalized probe
dosage. For the AUS study, the C4-ex30 probe failed to
produce a product. For those samples, total C4 dosage
was calculated from the mean of both C4A and C4B
Table 1 Summary characteristics of participating studies
Number of individuals Mean age (years) (SD) Females
Study Cases GA cases NV cases GA and NV cases Controls Total Cases Controls Cases (%) Controls (%)
AUS study 633 137 496 0 404 1037 75.95 (8.50) 71.03 (6.92) 64.60 55.40
WUE study 547 220 287 40 384 931 73.54 (6.74) 78.26 (5.30) 63.90 63.02
MUE/TUE study 356 97 129 130 321 677 76.16 (7.54) 69.50 (8.25) 64.89 55.80
Full study 1536 454 912 170 1109 2645 75.14 (7.78) 73.09 (7.83) 64.45 58.15
GA geographic atrophy, NV neovascular disease, SD standard deviation, AUS Australian study, WUE/MUE/TUE German study
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dosages. We show that this approach is feasible as there is
a strong correlation between total C4 dosage and the
mean of both, C4A and C4B dosage in the WUE and
MUE/TUE studies (Additional file 2: Figure S1). The nor-
malized probe dosages were ordered from low to high,
and subgroups corresponding to different DNA copy
numbers were calculated by determining the relative dif-
ferences between the subgroups. The distribution of copy
numbers of C4A, C4B, and total C4 in our controls was
comparable to previously reported distributions in healthy
individuals (Additional file 3: Table S2).
Direct PCR of C4 isoforms
To confirm homozygous deletions of C4A and C4B, we
performed a duplex PCR with two sets of isotype-
specific primers as described previously [21]. In brief,
PCRs were performed using Qiagen Hotstart Reagents
(www.qiagen.com) and oligonucleotide primers as listed
in Additional file 4: Table S3. The presence or absence
of the C4A and C4B genes was assessed in 2 % agarose gels.
Genotyping of AMD-associated variations in the CFB/C2
locus
Several previously reported AMD risk-associated varia-
tions in CFB and C2 are close to the C4 gene (a distance
of approximately 30,000 bp). Thus, known risk-associated
haplotypes carrying known AMD-associated variations
can potentially drive the association of C4 CNV. Recently,
a GWAS conducted by the International AMD Genomics
Consortium (IAMGDC) implicated four independent
signals in this locus to be associated with AMD [9].
We therefore determined the genotypes of four risk
variants to represent the four associated signals
(termed independent hit 8.1 to 8.4 in [9]). Two thousand
two hundred fifty-one DNA probes were genotyped on
the HumanCoreExome Chip (Illumina) as part of the
IAMDGC study. For those samples, we extracted the ge-
notypes of rs429608 (8.1), rs114190211 (8.2), rs204993
(8.3), and rs142511358 (8.4) and fit multivariate logistic
regression models additionally conditioned on those four
variants.
To further characterize the CFB/C2 locus, we used
SHAPEIT2 [22] with standard settings to phase the ge-
notypes and obtain the haplotypes. The association of
the resulting haplotypes with AMD risk was then ana-
lyzed in a multivariate logistic regression model adjusted
for age, gender, and study. In addition, since the phase
of the CNVs is difficult to estimate, we calculated the
average number of copies present on each haplotype to
identify haplotypes that carry C4A CNVs.
Statistical analysis and visualization
Copy number association analysis was carried out by lo-
gistic regression adjusted for age and gender and, where
appropriate, additionally adjusted for study [17]. All
analyses modeled an additive genetic effect, and the
genotype was coded as the number of gene copies
present at C4A, C4B, or total C4. As C4 copy number
was analyzed in three independent studies, we subse-
quently combined the obtained effect sizes (log odds
ratios) and standard errors from the three independ-
ent studies by conducting a meta-analysis assuming a
random effects model. We also assessed the evidence
for possible heterogeneity between the estimates from
each study by computing the I2 measure [23]. In the asso-
ciation analyses, the obtained P values were adjusted by a
conservative Bonferroni correction to account for multiple
testing assuming three independent tests due to three
CNVs analyzed.
We also performed association testing in groups of
individuals stratified by age, gender, and disease sub-
type (Additional file 5: Table S4 and Additional file 6:
Figure S2). The disease subtype-specific analyses com-
pared copy numbers of AMD patients with GA or
NV or mixed GA and NV to the copy numbers found
in all controls.
To account for possible differences in the association
between age groups, we stratified our case-control
study into three age categories with roughly equal sam-
ple size (1/3 of the total sample size). Accordingly, the
samples were assigned either to the youngest group
(<71 years old, 918 individuals), to the middle age
group (older than 71 years but younger than 78 years,
881 individuals), or to the oldest group (older than 78
years, 840 individuals). Similarly, cases and controls
were stratified by their gender and analyzed.
To assess whether the association of C4 ACNV with
AMD is independent of known AMD-associated signals
in this region, we fit logistic regression models addition-
ally conditioned on four AMD-associated SNPs at the
C2/CFB locus (rs429608, rs114190211, rs204993, and
rs142511358). Furthermore, the association of haplo-
types reconstructed from variations in the C2/CFB locus
were stratified by age and gender, adjusted for age and
study. The number of samples included in each analysis
is indicated by the size of the rectangles in Additional
file 6: Figure S2 and Additional file 7: Figure S3.
Results
Assessment of C4 gene copy number
The multiallelic CNV at theC4locus was assessed by
MLPA in three independent studies totalling 1536 late-
stage AMD cases of European descent and 1109 age and
ethnicity-matched AMD-free controls (Table 1). The
published MLPA probe sequences [24] were adapted to
facilitate the parallel assessment of the multiallelic CNV
forC4and its two isoforms C4A and C4B, despite the two
isoforms sharing >99 % sequence identity [25, 26]
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(Additional file 1: Table S1). We observed that the range
of copy numbers in control individuals was comparable to
distributions observed in previous studies of European
descent (Additional file 3: Table S2) [27, 28] and that the
distribution of copy number integers matched those re-
ported previously (C4A between 0 and 5 and C4B between
0 and 4) [29]. A comparison between cohorts revealed a
distinct clustering of results around several maxima,
corresponding to integer copy numbers (Fig. 1). As
homozygous deletions can be miscalled due to unex-
pected polymorphism at the site of ligation between
two MLPA probes [16], we confirmed all suspected
homozygous deletions by direct isotype PCR as previ-
ously described [21] and achieved 100 % concordance.
It has been suggested that batch effects could result
in differential bias leading to false-positive associa-
tions in quantitative data sets seeking to measure
complex multiallelic CNVs [13]. We therefore exam-
ined the distribution of raw unrounded probe dosages
for diploid copy number carriers for both C4A and
C4B or tetraploid copy number carriers for total C4
in cases and controls (Additional file 8: Table S5 and
Fig. 1). We found no evidence that mean distributions
were significantly different between cases and con-
trols, indicating that association results should repre-
sent true biological signals.
Association of C4 CNVs with AMD risk
Logistic regression models adjusted for age and gen-
der were computed for each study separately, and
meta-analyses of effect sizes and standard errors were
subsequently conducted assuming a random effects
model (Fig. 2). While there was no statistically signifi-
cant association for multiallelic CNVs at C4B or total
C4 with AMD (P > 0.05), we identified a statistically
significant association ofC4Acopy number with AMD
risk in each study (Puncorrected < 0.05, Fig. 2). In the
combined study and after correcting for multiple testing,
there was a highly significant association of C4A copy
number with AMD (P = 4.4 × 10−5,Pcorrected = 1.3 × 10
−4,
Fig. 2). We observed odds ratios (ORs) lower than one
per C4A copy, indicating a protective effect for each
additional C4A copy (OR 0.81 (0.73; 0.89)). In a sensitivity
analysis, C4A copy numbers from each independent study
were pooled and analyzed jointly. An unadjusted model
was fitted for C4A association (Additional file 5: Table S4)
identifying statistical significance with AMD in the pooled
study (OR 0.83 (0.76; 0.92)). We also computed a logistic
regression model adjusted jointly for age, gender, and
study and found ORs similar to the unadjusted model
(OR 0.82 (0.74; 0.90)) (Additional file 5: Table S4).
Sensitivity analysis of the observed C4A association
Next, we fitted logistic regression models to groups of
individuals stratified by age, gender, or disease pheno-
type adjusted for study. While no striking differences
were found between the three late-stage AMD disease
subtypes of only geographic atrophy (GA), only neovas-
cular AMD (NV) or both late-stage forms (GA and NV),
a striking difference between age groups and between
gender became apparent (Additional file 5: Table S4).
The observed protective association was stronger (more
protective per C4A copy) in individuals older than 78
years (OR 0. 67 (0.55; 0.81)) compared to individuals
between 71 and 78 years (OR 0.82 (0.74; 0.90)) and indi-
viduals younger than 71 years (OR 0.94 (0.79; 1.12)). Of
note, although we did not find a statistically significant
difference between the age groups (P > 0.05), this effect
Fig. 1 Normalized probe dosage quality control of complement C4A (a),C4B (b), and total C4 (c) in three independent studies. Distribution
of unrounded MLPA-based dosage estimates for 2645 individuals from three studies (AUS, WUE, and MUE/TUE) are shown. Distinct peaks
corresponding to integer copy numbers are demonstrated for C4A, C4B, and total C4. There is no obvious discrepancy in the distribution
of the normalized dosages between studies
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was present in each study individually. The observation
that the strength of the protective effect increases with
age is rather unexpected, as genetic associations tend
to show stronger effect sizes for adverse and protect-
ive alleles in younger individuals [30]. Next, our data
demonstrated thatC4Acopy numbers conferred a
stronger risk reduction in females (OR 0.77 (0.68;
0.87)) compared to males (OR 0.91 (0.77; 1.06)), al-
though the difference of observed effect sizes was not
statistically significant (P > 0.05). Finally, we investi-
gated the association in groups stratified by both, age
and gender, and found that particularly females in the
oldest age group (above 78 years) had the strongest
protective effect of additional C4A copies (Additional
file 6: Figure S2). Again, this effect was observed in a
similar fashion across the three studies.
C4A CNVs are associated with AMD independently of
CFB/C2 risk variants
Previous work showed a strong association of four in-
dependent signals in the complement factor B/com-
plement component 2 (CFB/C2) locus with AMD [9].
The CFB/C2 locus is in close proximity to the C4
gene on chromosome 6 which potentially could ex-
plain the observed association [27]. We therefore fit-
ted multivariate logistic regression models conditioned
on four SNPs at CFB/C2 (rs429608, rs114190211,
rs204993, and rs142511358) and found a protective,
although smaller and statistically no longer significant
effect per copy number when adjusting for these vari-
ants (OR 0.93 (0.82; 1.06)). This loss of association
was mainly driven by rs429608 (representing inde-
pendent hit IH8.1 in Ref. [9]), as C4A copy number
was significantly associated with AMD risk in a
model incorporating only rs114190211, rs204993, and
rs142511358 (OR 0.84 (0.75; 0.94)). Furthermore, the
reduction in effect sizes appeared to be predominantly
present in younger individuals and in males (Additional
file 6: Figure S2). The association remained strong and sig-
nificant in females (OR conditioned on CFB/C2 variants:
0.86 (0.74; 0.99)) and in individuals in the highest age
group (above 78 years, OR conditioned on CFB/C2 vari-
ants: 0.75 (0.61; 0.93)). Females in the oldest age category
(>78 years) showed a similar association of C4A copy
number with AMD in the conditioned and in the uncon-
ditioned model (OR unconditioned on CFB/C2 variants:
0.62 (0.48; 0.79), OR conditioned on CFB/C2 variants:
0.68 (0.52; 0.90)). The independence of association in the
latter group was observed across the three studies (OR of
C4A copy number conditioned on CFB/C2 variants in fe-
males older than 78 years in the (1) MUE/TUE study: 0.74
(0.40; 1.34)), (2) WUE study: 0.71 (0.48; 1.03), and (3) AUS
study: 0.55 (0.31; 0.94)).
C4A CNVs are found mainly on two AMD-associated
haplotypes in the CFB/C2 region
To further investigate the observed age and gender dif-
ference in the association of C4A CNVs, we used SHA-
PEIT2 to estimate the haplotypes in the CFB/C2 region.
In total, we found six different haplotypes (termed H1 to
H6) in this locus with an allele frequency above 1 % in
the current study (Additional file 9: Figure S4). The aver-
age C4A copy number was lower on the risk increasing
(adverse) haplotype H2 (characterized by the presence of
the risk increasing allele at rs204993) and higher on the
protective haplotype H3 (characterized by the presence
of the risk reducing allele at rs429608). Both observa-
tions are consistent with the observed risk reduction
with increasing C4A copy numbers. We therefore fo-
cused on the H2 and H3 haplotypes and investigated
their impact on the association of C4A copy number.
Fig. 2 Association analysis of multiallelic complement C4A (a),
C4B (b), and total C4 (c) copy numbers in AMD. Multivariate
logistic regression models, adjusted for age and gender, were
fitted for C4A, C4B, and total C4 copy number in each study. Log odds
ratios and standard errors obtained from each study were combined
and a meta-analysis performed assuming a random effects model. The
combined estimates for the odds ratios and 95 % confidence intervals
(CI) were computed from the random effects model. For C4B CNV,
there was statistically significant evidence for heterogeneity of the
effect sizes between the studies (Pheterogeneity < 0.05)
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Adverse haplotype H2 only marginally altered the associ-
ation of C4A CNV with AMD (OR C4A conditioned on
H2: 0.86 (0.77; 0.97)), indicating that the association of
C4A copy number with AMD risk is independent of
haplotype H2. Similar to the results obtained from the
single variant analysis, the haplotype H3 carrying the
protective allele at rs429608 reduced the association of
C4A CNV with AMD (OR C4A conditioned on H3: 0.92
(0.82; 1.03)). Consequently, we investigated the associ-
ation of H3 with AMD risk stratified by age and gender
(Additional file 9: Figure S4). While we failed to find a
difference in the strength of the association between
male and female, there was a correlation between in-
creasing age and association strength. The association
strength of the protective haplotype H3 decreased (less
protective) with increasing age, in line with previous re-
ports [30, 31]. Thus, it can be speculated that younger
individuals are protected from AMD by variations found
on protective haplotypes tagged by rs429608, while with
age C4A copy numbers take over (have a stronger effect)
and as such represent the main protective factor on
those haplotypes.
Discussion
Here, we performed a genetic association study of com-
plement C4CNVs in 1536 AMD cases and 1109 un-
affected controls from three independent studies [32].
This identified a strong protective association with an
increase in copy numbers of the C4A isoform. C4 is
known to play an important role in the activation of the
classical and lectin pathways of the complement system
[33, 34]. Although C4A and C4B share >99 % sequence
identity, C4A has been suggested to have a primary role in
immune complex clearance [26], greatly supported by the
strong association between systemic lupus erythematosus
(SLE) and low copy numbers of C4A [27, 28]. The involve-
ment of immune complexes have also been reported to
contribute to drusen formation [35], the earliest observ-
able phenotypic changes in AMD etiology. Genomic copy
numbers and serum C4A concentration are directly corre-
lated [24, 36], and increasing plasma concentrations of
C4A have been proposed to increase the clearance of im-
mune complexes [37]. It can be speculated that accumula-
tion of immune complexes are problematic in older
individuals with reduced C4A, and as such could partially
explain the observed increasing age-dependent association
we report in this study.
The C4 gene is located on chromosome 6p21 in the
MHC class III region around 30 kb proximal to the
CFB/C2 locus known to be strongly associated with
AMD [5, 38]. In SLE, physical proximity between C4
CNVs and variations at the CFB/C2 locus is thought to
partially explain the observed association signals [27]. In
contrast, in AMD, significant association of genes
flanking the C4 locus were suspected independently of
CFB/C2 variants [39, 40]. To further address the latter
issue, we investigated the association of C4A with AMD
risk after conditioning for four genetic variants known
to carry the main signals at the CFB/C2 locus [9]. As a
result, after conditioning, effect sizes and association
strength of C4A copy numbers are reduced and no lon-
ger statistically significant. The loss of association is
mainly driven by rs429608, as C4A copy number is sig-
nificantly associated with AMD in a model conditioned
on the remaining CFB/C2 variants, namely rs114190211,
rs204993, and rs142511358. However, the association of
C4A copy number with AMD in females and in individ-
uals beyond 78 years of age remains statistically signifi-
cant. Importantly, increased C4A copy number confers
similar risk reduction in females of the age group >78
years in the C2/CFB conditioned versus the uncondi-
tioned model. This independence of association was ob-
served across the three studies included in the analysis.
By analyzing AMD-associated haplotypes, we find C4A
copy number to be correlated to two AMD-associated
haplotypes in the CFB/C2 region (haplotypes H2 and
H3). We show that the association of C4A copy number
is independent of the adverse haplotype H2 but not of
the protective haplotype H3, the latter tagged by
rs429608. Importantly, we observed a strong reduction
in the protective effect of H3 in older individuals, in line
with previous results [30, 31]. These findings led us to
hypothesize that upon reduced protective impact of the
H3 haplotype on older individuals, C4A CNVs signifi-
cantly influence disease risk in this age group. In con-
trast, in younger individuals, the protective effect of the
H3 haplotype would be stronger and thus would account
for most of the protection conferred by the C2/CFB
locus in those individuals. With this in mind, our data
support the notion that older individuals reveal the CNV
at C4A to be associated with AMD risk independently of
known risk variations at the C2/CFB locus.
So far, AMD pathogenesis has primarily been linked to
dysregulation of the alternative pathway of the comple-
ment system [9]; however, expression analysis in cells of
the RPE-choroid complex has also identified compo-
nents and regulatory molecules associated with the clas-
sical pathway [41] and implicated classical complement
activation in various retinal degenerations [42]. More-
over, the presence of immunoglobulin G (IgG) and ter-
minal C5b-9 complement complexes as a component of
drusen deposits are indicative of classical pathway acti-
vation [35, 43]. These data, together with our findings in
this study, suggest the classical pathway, in addition to
the alternative pathway, to play a causal role in patho-
logical events leading to AMD disease.
The mechanisms underlying gender differences in
AMD risk are still unknown. We recently reported that
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genetic variants in the death-associated protein-like 1
(DAPL1) gene are associated with increased risk for
AMD, with risk association significantly higher in fe-
males than in males [17]. In the current study, we have
identified another gender-specific locus at C4A, in this
instance with a strong protective effect in females. Taken
together, these data provide a reasonable basis for fur-
ther investigations into the gender bias observed in
AMD prevalence.
We considered age to possibly be a confounding fac-
tor in this study as previous reports have linked copy
number of C4B and total C4 with longevity [44, 45].
However, in this study, we found no correlation between
total C4, C4A, or C4B copy number and age when includ-
ing all individuals in the calculations (P > 0.05). Addition-
ally, our AMD association analyses were adjusted for age,
which should satisfactorily account for confounding ef-
fects of longevity.
Conclusions
In conclusion, our results demonstrate that multiallelic
CNVs provide another source of genetic variance that
need to be considered in complex diseases such as
AMD. To date, an 84-kb deletion encompassing the
CFHR3/CFHR1 genes [46] and a small complex inser-
tion/deletion polymorphism in the ARMS2 gene [47]
represent the only CNVs to be reproducibly associated
with AMD disease. It is noteworthy that the CFHR3/
CFHR1 CNV is also associated with SLE, suggesting that
these two etiologies may share overlapping disease path-
ways. While our significance level does not reach current
standards of genome-wide significance (~5.00 × 10−8) for
new associated loci, it is questionable whether this
threshold is overly conservative for complex CNVs such
as C4, especially since we only investigated three mutu-
ally correlated CNVs. In addition, other replicated multi-
allelic CNV associations did not reach this threshold
[48]. Our finding that increased copy number of C4A is
associated with protection in AMD may have direct im-
plications for therapy, as targeted approaches to molecu-
lar constituents of the complement pathway have the
potential for early intervention before vision is compro-
mised. This is especially true, in very contrast to most
associated single nucleotide variants, as we can directly
implicate the relevant gene (C4A) and the orientation of
the protective effect with increased copy numbers and
thus with increased C4A protein levels in serum [49].
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Additional file 5: Table S4. Sensitivity analysis for C4A copy number
association. (DOCX 17 kb)
Additional file 6: Figure S2. Subgroup/sensitivity analysis in the
pooled study of C4A copy number. Odds ratios and corresponding
95 % confidence intervals are given with the size of each rectangle
representing the respective relative number of cases and controls in
each subgroup. The protective effect of increasing C4A copy number
is stronger in females and increases with age. Both effects can also
be observed when conditioning on known AMD associated risk
variants at the C2/CFB locus (rs429608, rs114190211, rs204993 and
rs142511358 [9]) and are present in each of the individual studies.
95 % confidence intervals are indicated; N stands for the total
number of individuals included in the analysis. (TIF 1946 kb)
Additional file 7: Figure S3. Sensitivity analysis for protective
haplotype H3 at the C2/CFB locus. Phase at C2/CFB was assessed with
SHAPEIT2 for each individual. Haplotypes are characterized by the
presence or absence of AMD associated alleles from four inpendent
variations at this locus (rs429608, rs114190211, rs204993 and rs142511358
[9]). Odds ratios and corresponding 95 % confidence intervals [95 % CI]
are given with the size of each rectangle representing the respective
relative number of cases and controls for each subgroup. The protective
effect of haplotype H3 decreases with age (becomes less protective). (TIF
1225 kb)
Additional file 8: Table S5. Mean dosages (S.D.) for diploid and
tetraploid cases and controls for C4A, C4B and totalC4. (DOCX 14 kb)
Additional file 9: Figure S4. AMD associated haplotypes at the C2/CFB
locus on chromosome 6. The phase at C2/CFB was assessed with
SHAPEIT2 for each individual. In total, we found six haplotypes (H1-H6)
with an allele frequency≥ 1 % in the study. The haplotypes are
characterized by the presence or absence of AMD associated alleles from
four inpendent variations at this locus (rs429608, rs114190211, rs204993
and rs142511358 [9]). C4A CNVs are predominantly present on the
adverse haplotype H2 (carrying the G allele of rs204993) and the
protective haplotype H3 (carrying the A allele of rs429608). OR = Odds
ratio, [95 % CI] = 95 % confidence intervals, SD = standard deviation. The
haplotypes were numbered according to their frequency. (TIF 2488 kb)
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